FDA Update

Breast Cancer

FDA Approves Giredestrant Plus Everolimus for ESR1-Mutant Advanced Breast Cancer

November 17 3 min read
On November 16, the oral estrogen receptor antagonist giredestrant (Wilserdly), in combination with everolimus, was approved for the treatment of adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, whose disease has recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting.

Latest in FDA Update